Monday, August 11, 2025 | 05:23 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

CureVac stock plunges after mRNA Covid vaccine falls short on protection

The shares plunged more than 52% in German trading, wiping out almost $9.6 billion in market value.

Photo: Bloomberg
premium

Photo: Bloomberg

Naomi Kresge and Tim Loh | Bloomberg
CureVac NV lost more than half its value after a preliminary analysis of a large study found its Covid-19 vaccine fell short of the high efficacy bar set by other messenger RNA shots.

The shares plunged more than 52% in German trading, wiping out almost $9.6 billion in market value.

The findings, though preliminary, throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. The spread of virus variants muddied the research, but other vaccines have shown they offer protection against those as well.

CureVac plans